---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-002720"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2026-04-27T23:59:59+00:00"
generated_at: "2026-05-15T03:53:47.965385+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Compass reports tovecimig hits PFS endpoint in BTC Ph2/3; plans BLA submission

## Summary
- Tovecimig + paclitaxel met key secondary PFS endpoint: median 4.7 vs 2.6 months (HR=0.44, p<0.0001).
- Primary ORR (previously announced) was 17.1% vs 5.3% (p=0.031); one complete response in tovecimig arm.
- OS endpoint not met due to 54% crossover; ITT OS 8.9 vs 9.4 months (HR=1.05, p=0.78).
- Crossover patients had median OS 12.8 months vs 6.1 months for non-crossover (HR=0.54, p=0.04).
- Company intends to meet with FDA to discuss data in advance of a planned BLA submission for second-line BTC.

## SEC filing metadata
- accession: 0001171843-26-002720
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2026-04-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/0001171843-26-002720-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/f8k_042526.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-002720
- JSON: https://secwatch.observer/filing/0001171843-26-002720.json
- Plain text: https://secwatch.observer/filing/0001171843-26-002720.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.